Ocutec, which is part of the Deepbridge Technology Growth EIS portfolio, has recently secured £1.5 million in a seed funding round that was led by Deepbridge Capital.

Summary of the Deepbridge Explore Webinar 

Simon Tutton, Regional Director (South West England and South Wales), Deepbridge Capital

Andrew Aldridge, Partner and Head of Marketing at Deepbridge, recently spoke with Professional Adviser to share his thoughts regarding the world of tax-efficient investments and assesses which relief is the trump card for advisers and clients.

Hy-genie, a portfolio company within the Deepbridge Life Sciences EIS fund, was a worthy winner of Business Cloud's MedTech 50 innovation ranking last year - with the help from Alder Hey Children's Hospital in its progress. 

One of the world's largest global wealth managers, UBS, has partnered with Fund Her North, working to improve access to finance for female-led businesses. 

Fund Her North is made up of over 28 women in venture capital, including Samantha Piddington (Head of Corporate Finance - Deepbridge Capital), funding organisations and angel groups with a combined investment power of over £450m. 

Deepbridge has today (19 January 2022) announced that Pathfinder Medical, a portfolio company within the Deepbridge Life Sciences EIS fund has secured a further £8.5 million funding round, led by BGF and Parkwalk.  

How do you find appropriate technology companies to invest in?
The Deepbridge team has decades of combined experience of working in and around the technology sector, both in the UK and internationally.  We therefore have strong networks which tend to refer investee opportunities to us and therefore we tend not to have to chase deals.  Having grown a reputation for providing smart capital to early-stage tech companies enables us to attract quality tech companies seeking growth funding.

Deepbridge can confirm that the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS currently have capacity for deployment prior to 5 April 2019, as Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS funds are usually deployed on a monthly basis. The earlier your clients funds are invested, the greater the chance that they will be invested in the current tax year.

Growing companies require expert guidance and mentoring as well as adequate funding to stay focused on their strategies, exploit new opportunities and prepare for the next stage of development or exit. Investments will only be made in companies where Deepbridge either engages with or has vetted experienced professionals to work with the management team. Deepbridge will take board positions in all investee companies and takes an “active role” to guide, mentor and counsel the management team.